Home » BioMarin Begins Phase IIIb Study Evaluating Kuvan on Neuropsychiatric Symptoms
BioMarin Begins Phase IIIb Study Evaluating Kuvan on Neuropsychiatric Symptoms
BioMarin Pharmaceutical announced on Tuesday that the first subject has initiated treatment in a Phase IIIb study to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria.
TradersHuddle
TradersHuddle
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May